Standard BioTools sells SomaLogic to Illumina for $425 million, streamlining operations and achieving EBITDA break-even.

From GlobeNewswire: 2025-06-23 07:05:00

Standard BioTools Inc. has announced the strategic sale of SomaLogic to Illumina, Inc. for up to $425 million, including $350 million in upfront cash. The sale also includes royalties on next-generation sequencing library preparation kits. This move simplifies operations for Standard BioTools and enables the achievement of adjusted EBITDA break-even. The transaction is expected to close in the first half of 2026, subject to regulatory approvals. Standard BioTools will continue to focus on disciplined M&A strategy to drive long-term value creation in the life sciences sector.



Read more at GlobeNewswire: Standard BioTools Enters Next Phase of Transformation with